Q-omics provides the consensus-scored GOT2 profile across patient tissues and cancer cell-line models. GOT2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GOT2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, GOT2 protein abundance shows 26,741 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KIRC, and GBM as cancer lineages where GOT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOT2 survival associations across molecular data types. GOT2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOT2 RNA expression–survival associations across cancer types. High GOT2 expression shows unfavorable associations in MESO, HNSC, SKCM and LUAD, but favorable associations in LIHC and KIRP. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for GOT2 RNA expression.
This table summarizes GOT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GOT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOT2 shows lower tumor expression in KIRC, THCA and LIHC and higher tumor expression in LUAD, COAD and LUSC. The KIRC box plot shows higher GOT2 RNA expression in normal versus tumor tissue (log2 FC = −1.083, t-test p < 0.001).
This table shows molecular features associated with GOT2 in patient tissues and cancer cell lines. In patient samples, GOT2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GOT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
